Status:
TERMINATED
A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
Lead Sponsor:
Eyetech Pharmaceuticals
Collaborating Sponsors:
Pfizer
Conditions:
Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving visi...
Eligibility Criteria
Inclusion
- Subjects of either gender, aged 50 years or greater.
- Subfoveal choroidal neovascularization (CNV) due to AMD.
- Best corrected visual acuity in the study eye between 20/40 and 20/320.
- Normal electroretinogram, and corneal endothelial cell density of 1500 cells/mm2 or more.
Exclusion
- Any prior photodynamic therapy (PDT) with Visudyne or thermal laser to the study eye.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
262 Patients enrolled
Trial Details
Trial ID
NCT00312351
Start Date
April 1 2006
End Date
November 1 2006
Last Update
January 15 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charlotte Eye, Ear, Nose and Throat Associates, P.A.
Charlotte, North Carolina, United States, 28210